Create
Log in
Enquire now
Prellis Biologics
Prellis Biologics is developing technology to build transplantable human organs and tissues.
Overview
Structured Data
Issues
Contributors
Access by API
Access by API
Is a
Company
Organization
Accelerator
IndieBio
AngelList URL
angel.co/prellis-biologics-1
B2X
B2B
Blog
medium.com/@Prellisbio
CEO
Melanie Matheu
Company Operating Status
Active
Competitors
Volumetric Bio
Contact Page URL
prellisbio.com/contact
Country
United States
Crunchbase URL
crunchbase.com/organiz...iologics
Email Address
jobs@prellisbio.com
media@prellisbio.com
info@prellisbio.com
Founded Date
2016
Founder
Noelle Mullin
0
Melanie Matheu
0
Headquarters
San Francisco
Accelerator Batch
IndieBio Class Five
Industry
Engineering
Healthcare
Regenerative medicine
Pharmaceutical industry
Organ transplantation
3D printing
Biomedical engineering
Tissue engineering
Bioprinting
Medicine
•••
Instagram URL
instagram.com/prellisbio/
Investors
True Ventures
Civilization Ventures
Cantos Ventures
415 Ventures
Khosla Ventures
Black Diamond Ventures
SOSV
Lucas Venture Group
Latest Funding Round Date
August 10, 2022
Latest Funding Round Amount (USD)
35,000,000
Latest Funding Type
Series C
LinkedIn URL
@company/prellis-biologics
Location
United States
San Francisco
Number of Employees (Ranges)
11 – 50
Patents Assigned (Count)
1
Pitchbook URL
pitchbook.com/profiles...182820-07
Place of Incorporation
United States
Total Funding Amount (USD)
87,952,758
Twitter URL
@prellisbio
Official Website
prellisbiologics.co
prellisbio.com
Wellfound ID
prellis-biologics-1
Find more companies like Prellis Biologics
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE